https://prabadinews.com/
  • October 9, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer

FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer

On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen Inc.) for adults with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. Tarlatamab-dlle received accelerated appro

administrator

Related Articles